TY  -  
T1  - Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment : study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study 
SN  -  /  
UR  - http://hdl.handle.net/10138/229032 
T3  -  
A1  - Glinatsi, Daniel; Heiberg, Marte S.; Rudin, Anna; Nordstrom, Dan; Haavardsholm, Espen A.; Gudbjornsson, Bjorn; Ostergaard, Mikkel; Uhlig, Till; Grondal, Gerdur; Horslev-Petersen, Kim; van Vollenhoven, Ronald; Hetland, Merete L. 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - Background: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Rheumatoid arthritis; Early treatment; Biological treatment; Aggressive conventional treatment; Sustained remission; De-escalation strategy; EARLY RHEUMATOID-ARTHRITIS; MODIFYING ANTIRHEUMATIC DRUGS; ADALIMUMAB PLUS METHOTREXATE; PLACEBO-CONTROLLED TRIAL; LOW DISEASE-ACTIVITY; COMBINATION THERAPY; RHEUMATOLOGY/EUROPEAN LEAGUE; RADIOGRAPHIC PROGRESSION; SUBCUTANEOUS ABATACEPT; INADEQUATE RESPONSE; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -